Article
Nanoscience & Nanotechnology
Lili Chen, Wenpeng Zhou, Ziyin Ye, Xiaoming Zhong, Jianwen Zhou, Shaohong Chen, Wei Liu, Yu Sun, Lijuan Ren, Xiaojun Tan, Ji Cui, Zhirong Zeng, Weiling He, Zunfu Ke
Summary: Based on the assessment of CTCs, this study found that CEP8 and CK-positive CTCs have the potential to improve the risk stratification of stage II CRC patients. In the subgroup with clinical high risk, the number of preoperative CTCs is associated with treatment outcome. Moreover, if postoperative CTC levels remain above 4 for more than three consecutive time points, the recurrence rate is 100%.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Immunology
Yijun Xu, Zhaosheng Li, Huina Shi, Mingchen Zhu
Summary: This study analyzed the distribution of immune cell subpopulations in peripheral blood samples from pancreatic cancer patients and investigated their correlation with clinical parameters and prognosis. The study found that pancreatic cancer patients had a decreased proportion of lymphocytes and an increased CD4/CD8 ratio. Increased proportions of lymphocytes and NKT cells were observed more frequently in patients over 60 years and in patients with metastasis. Furthermore, post-operative pancreatic cancer patients had significantly reduced proportions of CD4(+)T cells, B cells, and CD4/CD8 ratio, while the frequency of CD8(+)T cells and NKT cells was significantly elevated. Kaplan-Meier analysis indicated that patients with high lymphocyte proportion had prolonged overall survival.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Oncology
Kai Luo, Xiangkun Wang, Xudong Zhang, Zhongyuan Liu, Shuai Huang, Renfeng Li
Summary: In the past few decades, there have been developments in tumor diagnosis and treatment theory. However, pancreatic cancer mortality is increasing while the mortality rate of other common tumors is decreasing. Traditional imaging methods and biomarkers lack sensitivity and specificity for early micrometastasis detection. Circulating tumor cells (CTCs) have emerged as a non-invasive and real-time liquid biopsy technique with potential for analyzing tumor characteristics and serving as an independent prognostic factor.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Dannel Yeo, Althea Bastian, Heidi Strauss, Payal Saxena, Peter Grimison, John E. J. Rasko
Summary: This review summarizes the data on the utility of CTCs in PDAC and discusses the molecular profiling and culture methods of CTCs. CTCs have the potential to be used in screening, early diagnosis, prognostic assessment, and personalized management of PDAC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Hao Cheng, Jun Yang, Xu Fu, Liang Mao, Xuehui Chu, Chenglin Lu, Gang Li, Yudong Qiu, Wei He
Summary: In patients with pancreatic cancer, preoperative detection of FR(+)CTCs levels can predict survival and recurrence patterns after surgery, which is of great significance in guiding treatment strategies.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Young Hoon Choi, Tae Ho Hong, Seung Bae Yoon, In Seok Lee, Myung Ah Lee, Ho Joong Choi, Moon Hyung Choi, Eun Sun Jung
Summary: Portal venous circulating tumor cells (CTCs) can serve as a biomarker for early recurrence and poor prognosis in patients with resectable pancreatic cancer. The number of CTCs is associated with stage and regional lymph node metastasis, and low portal venous CTCs are associated with better overall and recurrence-free survival.
Article
Medical Laboratory Technology
Junliang Chen, Huaitao Wang, Lei Zhou, Zhihao Liu, Xiaodong Tan
Summary: This study found that circulating tumor cells (CTCs) could be used for the diagnosis of pancreatic ductal adenocarcinoma (PDAC) and had comparable sensitivity and specificity to CA199. Combining CA199 and CTC number could significantly improve the diagnostic performance of PDAC. CTC subtype was inferior to CTC number as a diagnostic marker.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Article
Medicine, Research & Experimental
Xiaoguang Wang, Lingyu Hu, Xiaodan Yang, Fei Chen, Haokai Xu, Haitao Yu, Zhengwei Song, Jianguo Fei, Zhengxiang Zhong
Summary: The study found that advanced PC patients who are CTC-positive are more likely to develop resistance to gemcitabine chemotherapy, have lower survival rates, and shorter progression-free survival.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2021)
Review
Oncology
Sung Woo Ko, Seung Bae Yoon
Summary: Despite advancements in PC diagnosis and treatment, clinical outcomes remain poor and there is a lack of effective prognostic biomarkers. CTCs, a promising biomarker, are rare in peripheral blood, but portal blood may offer better detection rates. Portal CTC counts are associated with hepatic metastasis, recurrence, and survival, providing information on tumor heterogeneity and prognosis. However, more prospective studies are needed to validate portal CTCs as a biomarker in PC.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2023)
Review
Oncology
Xingliang Fang, Huanrong Lan, Ketao Jin, Jun Qian
Summary: Pancreatic cancer is a highly dangerous disease, and understanding its progress and regression is crucial. Exosomes derived from various cells, including tumor cells, can impact the tumor microenvironment and play a role in cancer development. Detecting specific molecules carried by exosomes in blood and body fluids can aid in early diagnosis and monitoring of pancreatic cancer. Additionally, immune cell-derived exosomes and mesenchymal stem cell-derived exosomes have the potential for pancreatic cancer treatment through enhancing anti-tumor properties or drug loading. Overall, exosomes form a complex communication network that is involved in pancreatic cancer progression, diagnosis, monitoring, and treatment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jie Zhang, Yang Hong, Liang Wang, Weiheng Hu, Guangming Tian, Di Wu, Yang Wang, Ling Dai, Ziran Zhang, Yue Yang, Jian Fang
Summary: This study aimed to detect and describe the distribution characteristics of circulating tumor cells (CTCs) and circulating tumor-derived endothelial cells (CTECs) in patients with advanced lung cancer, and explore the correlation between CTC/CTEC subtypes and novel prognostic biomarkers. CTCs and CTECs derived from 52 patients with advanced lung cancer were identified using the subtraction enrichment-immunofluorescence in situ hybridization (SE-iFISH) system.
FRONTIERS IN ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Liang Chen, Shihua Luo, Zhilei Ge, Chunhai Fan, Yang Yang, Qian Li, Yuanqing Zhang
Summary: The research team established an unbiased enrichment method for CTCs using a DNAzyme-catalyzed strategy based on DNA framework. This method has higher enrichment efficiency and lower bias compared to traditional methods, providing a new solution for CTC-based cancer diagnostics.
Article
Oncology
Xiao Yang, Jiancheng Lv, Zijian Zhou, Dexiang Feng, Rui Zhou, Baorui Yuan, Qikai Wu, Hao Yu, Jie Han, Qiang Cao, Min Gu, Pengchao Li, Haiwei Yang, Qiang Lu
Summary: CTCs and CECs play a significant role in early intervention, treatment decision-making, and prognosis prediction in bladder cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Surgery
Qiao Zhang, Feng Xia, Qiang Sun, Wenjing Cao, Ali Mo, Weiming He, Jiazhen Chen, Weiqiao Zhang, Weiqiang Chen
Summary: This study aimed to investigate the effect of preoperative CTCs on postoperative recurrence and overall survival prognosis of pancreatic head cancer. The results showed that preoperative CTCs were significantly correlated with tumor invasion and postoperative metastasis, and were independent risk factors for DFS and OS.
FRONTIERS IN SURGERY
(2022)
Review
Oncology
Hyeon-Yeol Cho, Jin-Ha Choi, Joungpyo Lim, Sang-Nam Lee, Jeong-Woo Choi
Summary: The review highlights the significance of metastasis as the main cause of cancer-related death and discusses recent advances in the detection and analysis of circulating tumor cells and circulating cancer stem cells. The focus is on the design of microfluidic devices with optical sensing tools and strategies for analyzing the differentiation of circulating cancer stem cells.
